Oxabolone cipionate API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Oxabolone cipionate API 1254-35-9?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Oxabolone cipionate. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Oxabolone cipionate
- Synonyms:
- 4-hydroxy-19-nortestosterone 17β-cypionate , Cipionate d'oxabolone , Cipionato de oxabolona , Oxabolone 17-cyclopentanepropionate , Oxabolone cypionate , Oxaboloni cipionas
- Cas Number:
- 1254-35-9
- DrugBank number:
- DB13185
- Unique Ingredient Identifier:
- 5RXY50Q01N
General Description:
Oxabolone cipionate, identified by CAS number 1254-35-9, is a notable compound with significant therapeutic applications. Oxabolone cipionate is the C17β cypionate ester and a prodrug of . A synthetic anabolic-androgenic (AAS) steroid, it is a derivative of 19-nortestosterone (nandrolone). It is considered as a performance enhancing drug thus is prohibited from use in sports.
Indications:
This drug is primarily indicated for: Used as a performance enhancing drug illicitly in athletes. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.
Metabolism:
Oxabolone cipionate undergoes metabolic processing primarily in: The prodrug oxabolone cipionate is converted to oxabolone. Oxabolone is then metabolized into 4-Hydroxyestr-4-en-3,17-dione (M2) which is the most abundant metabolite via oxidation of the 17-hydroxyl group. 4-Hydroxyestran-3,17-dione (M1) is formed by reduction of the A ring double bond along with the oxidation of the 17-hydroxyl group. Three isomeric compounds exist as another metabolite, as the 3α,4-dihydroxy-5α-estran-17-one, 3α,4-dihydroxy-5β-estran-17-one, and 3β,4-dihydroxy-5α-estran-17-one . This metabolic pathway ensures efficient processing of the drug, helping to minimize potential toxicity and side effects.
Route of Elimination:
The elimination of Oxabolone cipionate from the body primarily occurs through: The metabolites and unchanged form of oxabolone can be detected in the urine . Understanding this pathway is essential for assessing potential drug accumulation and toxicity risks.
Clearance:
The clearance rate of Oxabolone cipionate is a critical factor in determining its safe and effective dosage: The elimination on the first day following intravenous injection of oxabolone cipionate is slow and reaches a rapid excretion phase with the maximum urinary level in the fifth day of administration . It reflects the efficiency with which the drug is removed from the systemic circulation.
Pharmacodynamics:
Oxabolone cipionate exerts its therapeutic effects through: Androgenic effects include enhanced secondary sexual characteristics. The drug's ability to modulate various physiological processes underscores its efficacy in treating specific conditions.
Classification:
Oxabolone cipionate belongs to the class of organic compounds known as steroid esters. These are compounds containing a steroid moiety which bears a carboxylic acid ester group, classified under the direct parent group Steroid esters. This compound is a part of the Organic compounds, falling under the Lipids and lipid-like molecules superclass, and categorized within the Steroids and steroid derivatives class, specifically within the Steroid esters subclass.
Categories:
Oxabolone cipionate is categorized under the following therapeutic classes: Alimentary Tract and Metabolism, Anabolic Agents for Systemic Use, Anabolic Steroids, Drugs that are Mainly Renally Excreted, Estradiol Congeners, Estranes, Estren Derivatives, Estrenes, Fused-Ring Compounds, Gonadal Hormones, Gonadal Steroid Hormones, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Steroids. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Oxabolone cipionate is a type of Gastrointestinal Agents
Gastrointestinal Agents belong to the pharmaceutical API category that focuses on treating disorders and ailments related to the digestive system. These agents play a crucial role in addressing various gastrointestinal conditions, such as acid reflux, ulcers, irritable bowel syndrome (IBS), and inflammatory bowel disease (IBD).
One of the key types of gastrointestinal agents is proton pump inhibitors (PPIs), which work by reducing the production of stomach acid. PPIs help in treating conditions like gastroesophageal reflux disease (GERD) and peptic ulcers. Another essential class of agents is antacids, which neutralize excessive stomach acid, providing relief from heartburn and indigestion.
Gastrointestinal agents also include antispasmodics that alleviate abdominal cramps and spasms associated with conditions like IBS. These drugs work by relaxing the smooth muscles of the digestive tract. Additionally, there are drugs categorized as laxatives that aid in relieving constipation by promoting bowel movements.
Moreover, certain gastrointestinal agents act as antiemetics, effectively reducing nausea and vomiting. These drugs are particularly useful for patients undergoing chemotherapy or experiencing motion sickness.
Pharmaceutical companies develop and manufacture a wide range of gastrointestinal agents in various forms, including tablets, capsules, suspensions, and injections. These agents are typically formulated using active pharmaceutical ingredients (APIs) and other excipients to ensure their efficacy and safety.
In conclusion, gastrointestinal agents form a vital category of pharmaceutical APIs, providing relief from digestive disorders and improving overall gastrointestinal health. The availability of diverse agents catering to different conditions ensures that patients can receive targeted treatment for their specific gastrointestinal needs.
